CompletedPhase 4

Rate Control in Atrial Fibrillation II

Norway122 participantsStarted 2016-02

Plain-language summary

The RATAF II study is a randomized, prospective, parallel group study, designed to compare the effects of two different drug regimens for rate control in permanent AF (atrial fibrillation). We will investigate on the difference in effects on exercise capacity, biomarkers (NT-proBNP (N-terminal pro-brain natriuretic peptide), troponins, hs-CRP), heart rate, echocardiographic measurements and symptoms. Our main hypothesis is that six months' treatment with the calcium channel blocker diltiazem will lower NT-proBNP and increase exercise capacity (peak VO2) compared to treatment with the beta blocker metoprolol in permanent AF.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Above 18 years of age * Symptomatic, permanent AF of at least three months duration * Resting heart rate ≥80 bpm * Signed informed consent Exclusion Criteria: * Congestive heart failure * Ischemic heart disease * Hypotension (Systolic blood pressure \<100 mmHg) * Treatment with class I or III antiarrhythmic drugs * Severe hepatic or renal failure * Pregnancy or lactation * Hypersensitivity or contradictions to study drugs * Atrio-ventricular conduction disturbances * Thyrotoxicosis * Life limiting disease or substance abuse which may affect participation

What they're measuring

Levels of NT-proBNP

Timeframe: 4 weeks

Levels of NT-proBNP

Timeframe: 6 months

Trial details

NCT IDNCT02695992

SponsorAsker & Baerum Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-10

View on ClinicalTrials.gov More Atrial Fibrillation trials